PTPN22 and cancer: Addressing current therapy limitations is essential, especially considering that certain cancer patients with the rs2476601 variant exhibited enhanced responses to checkpoint inhibitor immunotherapy, highlighting PTPN22’s relevance as a druggable systemic target for cancer treatment [6,7].